Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1693948

	registered interest
	date	05/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many medicine supply issue notifications her Department has received in each month since 2017.
	tabling member constituency	Birmingham, Edgbaston
	tabling member printed	Preet Kaur Gill
	uin	17245
	answer	answer is ministerial correction date of answer 21/03/2024 answer text <p>There are around 14,000 licensed medicines, and the overwhelming majority are in good supply. However, the medicine supply chain is highly regulated, complex, and global and supply disruption is an issue which affects countries all around the world.</p><p>The Department’s medicines Discontinuations and Shortages (DaSH) portal was established in October 2020 to collect notifications from suppliers of potential supply issues. Data from before October 2020 cannot be provided as this information is not held. The following table shows the number of supply issue notifications added to the DaSH portal, each month since 2020:</p><table><tbody><tr><td><p>Month added to DaSH</p></td><td><p>Number of supply issue notifications</p></td></tr><tr><td><p>October 2020</p></td><td><p>180</p></td></tr><tr><td><p>November 2020</p></td><td><p>130</p></td></tr><tr><td><p>December 2020</p></td><td><p>90</p></td></tr><tr><td><p>January 2021</p></td><td><p>90</p></td></tr><tr><td><p>February 2021</p></td><td><p>70</p></td></tr><tr><td><p>March 2021</p></td><td><p>60</p></td></tr><tr><td><p>April 2021</p></td><td><p>50</p></td></tr><tr><td><p>May 2021</p></td><td><p>60</p></td></tr><tr><td><p>June 2021</p></td><td><p>130</p></td></tr><tr><td><p>July 2021</p></td><td><p>60</p></td></tr><tr><td><p>August 2021</p></td><td><p>100</p></td></tr><tr><td><p>September 2021</p></td><td><p>90</p></td></tr><tr><td><p>October 2021</p></td><td><p>80</p></td></tr><tr><td><p>November 2021</p></td><td><p>100</p></td></tr><tr><td><p>December 2021</p></td><td><p>100</p></td></tr><tr><td><p>January 2022</p></td><td><p>110</p></td></tr><tr><td><p>February 2022</p></td><td><p>130</p></td></tr><tr><td><p>March 2022</p></td><td><p>70</p></td></tr><tr><td><p>April 2022</p></td><td><p>100</p></td></tr><tr><td><p>May 2022</p></td><td><p>120</p></td></tr><tr><td><p>June 2022</p></td><td><p>140</p></td></tr><tr><td><p>July 2022</p></td><td><p>210</p></td></tr><tr><td><p>August 2022</p></td><td><p>140</p></td></tr><tr><td><p>September 2022</p></td><td><p>180</p></td></tr><tr><td><p>October 2022</p></td><td><p>130</p></td></tr><tr><td><p>November 2022</p></td><td><p>180</p></td></tr><tr><td><p>December 2022</p></td><td><p>110</p></td></tr><tr><td><p>January 2023</p></td><td><p>170</p></td></tr><tr><td><p>February 2023</p></td><td><p>130</p></td></tr><tr><td><p>March 2023</p></td><td><p>140</p></td></tr><tr><td><p>April 2023</p></td><td><p>120</p></td></tr><tr><td><p>May 2023</p></td><td><p>120</p></td></tr><tr><td><p>June 2023</p></td><td><p>130</p></td></tr><tr><td><p>July 2023</p></td><td><p>130</p></td></tr><tr><td><p>August 2023</p></td><td><p>160</p></td></tr><tr><td><p>September 2023</p></td><td><p>110</p></td></tr><tr><td><p>October 2023</p></td><td><p>130</p></td></tr><tr><td><p>November 2023</p></td><td><p>170</p></td></tr><tr><td><p>December 2023</p></td><td><p>140</p></td></tr><tr><td><p>January 2024</p></td><td><p>160</p></td></tr></tbody></table> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 21/03/2024 13:57:11 answering member 4044 label Biography information for Andrew Stephenson previous answer version 22710 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4603 label Biography information for Preet Kaur Gill

1685919

	registered interest
	date	30/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to secure supplies of medicines for (a) diabetes, (b) cancer and (c) mental health treatments.
	tabling member constituency	Stirling
	tabling member printed	Alyn Smith
	uin	12108
	answer	answer is ministerial correction date of answer 05/02/2024 answer text <p>The Department has well-established tools and processes to manage supply issues whenever they arise, helping to prevent shortages and mitigate risks to patients. We work with industry, NHS England, the Medicines and Healthcare products Regulatory Agency, devolved administrations and other stakeholders to help ensure patients continue to have access to the treatments they need.</p><p>The Department has been working with industry to help boost supplies of medicines for the treatment of type 2 diabetes, and the position is improving as a result. Some supply issues remain, but we are continuing to work hard to resolve these as quickly as possible. We have issued guidance to all healthcare professionals on how to manage patients requiring these medicines whilst supply is disrupted. Our guidance is clear that medicines licensed for the treatment of type 2 diabetes should only be used for this purpose.</p><p>Regarding cancer medicines, we are aware of an issue with the supply of letrozole tablets from one supplier. We have been working with alternative suppliers, who have confirmed that they have the stock available to meet demand. A supplier of tamoxifen tablets is also experiencing supply issues, but again we have worked with alternative suppliers to help ensure they can support the market at this time.</p><p>Regarding medicines for mental health treatments, the Department has been working with manufacturers of attention deficit hyperactivity disorder medicines and a number of issues have now been resolved. Work continues to resolve the remaining supply issues by April 2024. We have issued a National Patient Safety Alert and worked with clinicians to develop helpful guidance on how to manage patients during this time.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 05/02/2024 15:34:52 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4738 label Biography information for Alyn Smith

1452003

	registered interest
	date	16/03/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what links there are (1) legally, (2) administratively, and (3) financially, between the Medicines and Healthcare products Regulatory Agency and pharmaceutical companies.
	tabling member printed	Lord Framlingham
	uin	HL7016
	answer	answer is ministerial correction date of answer 24/03/2022 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is an independent regulator working on a nominal fee for licence applications and regulating the industry. The MHRA is funded predominantly by income from fees for both statutory and non-statutory sales of products and services, which includes working with pharmaceutical companies.</p><p>As civil servants, all staff are committed to the core values of integrity, honesty, objectivity and impartiality. Additionally, staff are not permitted to have any personal financial connections to pharmaceutical companies or medical device manufacturers.</p> answering member printed Lord Kamall question first answered 24/03/2022 15:52:54 answering member 4909 label Biography information for Lord Kamall
	tabling member	134 label Biography information for Lord Framlingham

1277359

	registered interest
	date	18/01/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they are taking to support and advise NHS Trusts on ‘ready to use’ medicines which (1) improve patient safety through reduced drug administration errors, (2) save nursing time, and (3) relieve pressure on pharmacy teams.
	tabling member printed	Baroness Masham of Ilton
	uin	HL12227
	answer	answer is ministerial correction date of answer 01/02/2021 answer text <p>The noble Lord Carter of Coles published a report last year on the provision of aseptic medicines, including some critical care medicines, in England. Recommendations included setting up a network of hub and spoke facilities to prepare ready to administer medicines, providing guidance on standard injectable medicines, and training for aseptic pharmacy staff. NHS England and NHS Improvement are setting up a National Health Service aseptic services transformation implementation board to co-ordinate the implementation of these recommendations.</p><p>The recommended changes will improve patient safety by reducing errors in compounding and administering these medicines. Errors in these medicines are not currently specifically tracked but the report recommends that the NHS begins tracking and reducing them.</p><p>The creation of regional hub and spoke services could release the equivalent of over 4,000 whole time equivalent nurses each year. This is based on the time taken for nurses to prepare the 14 most commonly used aseptic medicines. The development of a hub and spoke system will offer opportunities for production at scale, relieving pressure on hospital pharmacies.</p> answering member printed Lord Bethell question first answered 01/02/2021 12:39:37 answering member 4708 label Biography information for Lord Bethell
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1243075

	registered interest
	date	13/10/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the extent of stockpiling of medicines in preparation for (a) a second wave of covid-19 and (b) the end of the transition period, and if he will publish that assessment.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Dame Diana Johnson
	uin	102708
	answer	answer is ministerial correction date of answer 22/10/2020 answer text <p>As part of our concerted national efforts to respond to the COVID-19 outbreak, we are doing everything we can to ensure patients continue to have access to COVID-19 medicines in all scenarios. This includes holding stockpiles of a variety of medicines currently and potentially used in treating patients with COVID-19, to help ensure there is uninterrupted supply over the coming months.</p><p>As set out in a letter from the Department to industry of 3 August, we are implementing a multi-layered approach to the end of the Transition Period, that involves asking suppliers of medicines and medical products to the United Kingdom from or via the European Union to get trader ready, reroute their supply chains away from any potential disruption and stockpiling to a target level of six weeks on UK soil where this is possible. The letter is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020" target="_blank">https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020</a></p><p>Any information on suppliers’ stock levels that has been shared with the Department to support contingency planning is commercially sensitive and cannot be shared with third parties.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 22/10/2020 09:41:33 answering member 4380 label Biography information for Jo Churchill
	tabling member	1533 label Biography information for Dame Diana Johnson

1231229

	registered interest
	date	03/09/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the public have uninterrupted access to over the counter medicines in the event of the UK leaving the EU without a deal.
	tabling member constituency	Oxford West and Abingdon
	tabling member printed	Layla Moran
	uin	84734
	answer	answer is ministerial correction date of answer 10/09/2020 answer text <p>The Department, in consultation with the devolved administrations and Crown Dependencies, is working with trade bodies, product suppliers, and the health and care system in England to make detailed plans to help ensure continued supply of medicines and medical products, including medical radioisotopes and over-the-counter medicines, to the whole of the United Kingdom at the end of the transition period in all scenarios.</p><p>The Department understands that a flexible approach to preparedness may be required for medicines that cannot be stockpiled, such as some medical radioisotopes. We have asked suppliers of those products to use airfreight, which some suppliers are already doing now.</p><p> </p><p>Further detail on the plans to help ensure continuity of medical supplies has been communicated to suppliers, and can be found at the following link:</p><p><a href="https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020" target="_blank">https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020</a></p><p> </p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 84731 question first answered 10/09/2020 18:16:23 answering member 4362 label Biography information for Edward Argar previous answer version 45730 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4656 label Biography information for Layla Moran

1203560

	registered interest
	date	15/06/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government what assessment they have made about whether any drugs or medicines will be in short supply after the UK leaves the EU.
	tabling member printed	Lord Roberts of Llandudno
	uin	HL5715
	answer	answer is ministerial correction date of answer 30/06/2020 answer text <p>The United Kingdom left the European Union on 31 January and is now in a Transition Period until 31 December 2020. During this time, it remains our objective to negotiate a future relationship with the EU and in our respective published negotiating documents, we have both stated objectives to reach an agreement on trade in goods. The UK’s published approach sets out how we want to facilitate trade in medicinal products and support high levels of patient safety.</p><p>The Government, pharmaceutical industry and National Health Service will always work closely together to help ensure patients continue to have access, to the medicines and treatments they need, including insulin, under all scenarios.</p><p>The Department has well-established procedures to deal with medicine shortages and is working closely with industry, the NHS and others in the supply chain to reduce the likelihood of future shortages resulting from any cause.</p><p> </p> answering member printed Lord Bethell grouped question UIN HL5713 question first answered 30/06/2020 15:47:39 answering member 4708 label Biography information for Lord Bethell
	tabling member	3691 label Biography information for Lord Roberts of Llandudno

1186624

	registered interest
	date	19/03/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to manufacture more active pharmaceutical ingredients in the UK to prevent medicine shortages.
	tabling member constituency	Coventry North West
	tabling member printed	Taiwo Owatemi
	uin	32261
	answer	answer is ministerial correction date of answer 14/04/2020 answer text <p>The Government has no plans to create facilities in the United Kingdom to manufacture further active pharmaceutical ingredients. There are 16,000 medicines on the market in the UK. Whilst some of these are manufactured in the UK, most are manufactured abroad. Where medicines are manufactured here, the active ingredients and excipients for those medicines may be manufactured abroad. It is not realistic to manufacture all 16,000 medicines and the active ingredients and excipients needed for these medicines in the UK.</p><p>The production of medicines is complex and highly regulated, and materials and processes must meet rigorous safety and quality standards. Supply problems can affect a wide range of medicines and can arise for various reasons, such as manufacturing issues, problems with the raw ingredients and batch failures. These problems arise regardless of where in the world the manufacture takes place.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 14/04/2020 14:50:24 answering member 4380 label Biography information for Jo Churchill previous answer version 14443 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4779 label Biography information for Taiwo Owatemi

1027714

	registered interest
	date	18/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer on 11 September to Question number 169109 on Social Care: Drugs, (a) when the 2019-20 planning process was completed and (b) what the level of funding is for the 2019-20 prioritisation process.
	tabling member constituency	Alyn and Deeside
	tabling member printed	Mark Tami
	uin	203288
	answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>The independently chaired Clinical Priorities Advisory Group met in November 2018 to make prioritisation recommendations for investments in specialised service for the 2019/20 financial year. Final investment decisions will be announced shortly. A second prioritisation round for investment in 2019/20 will be held next year.</p><p> </p><p>The baseline budget for prioritisation in 2019/20 has been set at £25.7 million reflecting a 2.7% increase on the 2018/19 budget. The availability of any additional funding to support prioritisation will be kept under review between now and May/June 2019 when the second round of investment decisions will be taken for the 2019/20 financial year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/12/2018 15:58:15 answering member 4067 label Biography information for Steve Brine
	tabling member	1383 label Biography information for Mark Tami

964339

	registered interest
	date	03/09/2018
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, if his Department will make an assessment of the potential merits of reclassifying (a) GHB (b) GHL as a Class A substance.
	tabling member constituency	Brighton, Kemptown
	tabling member printed	Lloyd Russell-Moyle
	uin	169718
	answer	answer is ministerial correction date of answer 26/09/2018 answer text <p>GHB and GBL are controlled as class C drugs under the Misuse of Drugs Act 1971. As with all controlled drugs we will continue to monitor their impact and the potential merits of reclassification.</p><p> </p> answering member constituency Louth and Horncastle answering member printed Victoria Atkins question first answered 26/09/2018 12:17:02 answering member 4399 label Biography information for Victoria Atkins
	tabling member	4615 label Biography information for Lloyd Russell-Moyle